Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
about
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanomaChemoimmunotherapy versus chemotherapy for metastatic malignant melanomaSystematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanomaBiochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma: results of a phase II trial.Treatment of malignant melanoma.Strategies for combining chemotherapy and biotherapy in melanoma.A review of evidence-based treatment of stage IIB to stage IV melanoma.Chemotherapy for metastatic melanoma.Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance.Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2.Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine.Immunotherapy of distant metastatic disease.Metastatic melanoma - a review of current and future drugsNovel therapeutics for the treatment of metastatic melanoma.Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma.Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
P2860
Q24246409-8A685344-712B-4911-8355-D0B7CC01599DQ24246853-8B01BBDB-A39F-4C3C-B703-D55676D50643Q26996629-7FCB62C0-3A6A-4299-AA97-38AB6DD1A28BQ33368188-8D6B4BF7-7F34-4CCC-90F7-D38797FC68C2Q33689227-B6346962-505A-4856-8EDC-27A0565F0431Q33900416-55F9BEE3-3AA9-4DA7-BFBE-B49DAABC47FBQ36229746-01ED884B-5677-43A1-BB01-50019553D6DCQ36352095-F22E7184-FA12-4AB9-A7C0-ABC928A2879DQ36620866-7A13E544-A01C-4BEB-AD88-7E7F40E66DD9Q36621278-6DB3CBF8-3FB4-4BF7-B478-45F530FB3125Q36643649-332F3AEB-7372-4C24-BDCE-3A99E98D81C0Q36691820-AE1DE940-AC1A-4140-B22B-5E48BC252F7FQ36826045-254E1E37-A762-48E2-A583-84E0FCCF69AEQ36980823-255205AE-07D9-4247-BDF8-C398476FE4E7Q37266668-DF4DD7FA-E172-4B9E-9A66-30F784A11B4CQ37450733-11B1C309-AFE9-4730-B155-292344A79865Q37486788-3E8372DE-281A-4AF9-A8B1-1E0D28BA7489Q46515640-AD87613C-FB76-4241-8DD6-179A951830F5Q46527499-A5A4CE9F-ED33-4119-92B2-8DD194C7CE4A
P2860
Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
description
1998 nî lūn-bûn
@nan
1998 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Randomized phase II trial of B ...... ents with metastatic melanoma.
@ast
Randomized phase II trial of B ...... ents with metastatic melanoma.
@en
type
label
Randomized phase II trial of B ...... ents with metastatic melanoma.
@ast
Randomized phase II trial of B ...... ents with metastatic melanoma.
@en
prefLabel
Randomized phase II trial of B ...... ents with metastatic melanoma.
@ast
Randomized phase II trial of B ...... ents with metastatic melanoma.
@en
P2093
P2860
P356
P1476
Randomized phase II trial of B ...... ents with metastatic melanoma.
@en
P2093
Atkinson H
Constenla DO
Johnston SR
P2860
P2888
P304
P356
10.1038/BJC.1998.214
P407
P577
1998-04-01T00:00:00Z
P5875
P6179
1025552168